US presence is a must for biologics producers, says Recipharm

By Gareth Macdonaold

- Last updated on GMT

Related tags: United states, Biologics

US presence is a must for biologics producers, says Recipharm
Recipharm CEO Thomas Eldered reflects on RecipharmCobra Biologics (RCB) launch, telling Outsourcing-pharma that US is key market.

Eldered said that new unit, which opened for business in February​, builds on the Swedish contract development and manufacturing group’s existing biologics capacity by adding those of recent acquisition, UK-based, Cobra Biomanufacturing.

He explained that in addition to its reputation in the biologics manufacturing field, Cobra’s presence in the US market through its commercial office in Chicago was a key driver for the original deal.

“The US is the biggest market in the world and, as such, is [a market] where you have to be present​,” continued Eledred, before high that Cobra’s specialist manufacturing capability and process development team was also a factor.

And, in more general terms, Eldered said that a strong biologics manufacturing infrastructure is going to be important for CDMOs going forward.

All the large pharma companies are rapidly expanding their biologics pipelines and if we don’t expand our capabilities in this area in this area we would be ignoring a fast growing and very significant market​.”

Related news

Show more

Related product

Why Blister Packaging: Things to Consider

Why Blister Packaging: Things to Consider

Catalent Pharma Solutions | 03-Dec-2020 | Insight Guide

The decision to use blister packaging for either clinical trials or commercial drug manufacturing comes with a host of factors to consider. Pharmaceutical...

Related suppliers

Follow us

Products

View more

Webinars